Compare Hims and Hers Health Inc (HIMS) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Las Vegas Sands Corp. — how do they compare? Hims and Hers Health Inc trades at $29.3 (market cap $6.55B), while Las Vegas Sands Corp. trades at $36.03 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 3.6× Hims and Hers Health Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Las Vegas Sands Corp. for 72 Days on average.
| HIMS | LVS | |
|---|---|---|
Market Cap | $6.55B | $23.38B |
Volume | 14,842,814 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $69.49 |
52-Week Low | $14.52 | $35.81 |
Typical Hold Time | 21 Days | 72 Days |
Enterprise Value | $7.25B | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
LVS trades at $36.15, up 0.95% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $13.02B in 2025 and a net income of $1.63B, with a P/E of 13.99 suggesting reasonable valuation. Recent news highlights Sands China's community initiatives and awards, while Q2 2026 earnings missed expectations.
The investment outlook is mixed: analyst consensus is bullish with a $59.78 price target, but high debt levels and a recent earnings miss pose risks. Upside potential exists if the company maintains revenue growth and executes its stock repurchase program, though sensitivity to Macao's tourism recovery and interest rates remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
